Editas Medicine (EDIT) Debt Ratio (2016 - 2025)
Editas Medicine (EDIT) posted quarterly Debt Ratio of 0.31 for Q4 2025, up 86.86% year-over-year from 0.17 in Q4 2024, and up 7.31% quarter-over-quarter from 0.29 in Q3 2025.
Editas Medicine (EDIT) Debt Ratio (2016 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Debt Ratio for 4 consecutive years, with 0.31 the latest figure, recorded in Q4 2025.
- In Q4 2025, Debt Ratio rose 86.86% year-over-year to 0.31; the TTM figure through Dec 2025 stood at 0.31 (up 86.86% YoY), while the FY2025 annual figure was 0.31, up 86.86% from the prior year.
- Debt Ratio climbed to 0.31 in Q4 2025 per EDIT's latest filing, from 0.29 in the prior quarter.
- Across five years, Debt Ratio topped out at 0.31 in Q4 2025 and bottomed at 0.17 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.05 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.12 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.47 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.26 |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - | 0.31 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.31 |
| Sep 30, 2025 | 0.29 |
| Jun 30, 2025 | 0.27 |
| Mar 31, 2025 | 0.21 |
| Dec 31, 2024 | 0.17 |
| Dec 31, 2017 | 0.02 |
| Jun 30, 2017 | 0.04 |
| Mar 31, 2017 | 0.04 |
| Dec 31, 2016 | 0.04 |